natgillin/translations-raw huggingface dataset:
Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or using machines). 
Ne pozabite na to v okoliščinah, v katerih bi lahko ogrozili sebe in druge (kot sta vožnja avtomobila ali upravljanje strojev).
Lantus with alcohol 
Zdravilo Lantus skupaj z alkoholom
-In your brain 
V vaših možganih
In patients with type 2 diabetes mellitus, Lantus can also be given together with orally active antidiabetic medicinal products. 
Pri bolnikih z diabetesom mellitusom tipa 2 je mogoče zdravilo Lantus uporabljati tudi skupaj s peroralnimi antidiabetičnimi zdravili.
To ensure that you read the dose correctly, hold the pen horizontally, with the needle on the left and the dosage selector to the right as shown in the illustrations below. 
Da boste zagotovo pravilno prebrali količino odmerka, držite injekcijski peresnik vodoravno, z injekcijsko iglo na levi in dozirnim rezervoarjem na desni, kot je prikazano na spodnji sliki.
• If the needle is not kept straight while you attach it, it can damage the rubber seal and cause leakage, or break the needle. 
• Če igle med nameščanjem ne držite naravnost, lahko poškoduje gumijasto zaporo in povzroči iztekanje, ali pa se igla zlomi.
The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure (coronary, carotid, or peripheral), or hospitalisation for heart failure. 
Prvi soprimarni izid učinkovitosti je bil čas do prvega pojava KV smrti, miokardnega infarkta (MI) brez smrtnega izida ali možganske kapi brez smrtnega izida, sekundarni soprimarni izid učinkovitosti pa je bil čas do prvega pojava katerega koli prvega soprimarnega dogodka ali revaskularizacijskega posega (koronarnega, karotidnega ali perifernega) ali hospitalizacije zaradi srčnega popuščanja.
There were no differences between insulin glargine and standard care for the two co-primary outcomes; for any component endpoint comprising these outcomes; for all-cause mortality; or for the composite microvascular outcome. 
Med insulinom glarginom in standardno oskrbo ni bilo razlik glede obeh soprimarnih izidov, glede nobene komponente opazovanega dogodka, ki je obsegal te izide, glede umrljivosti zaradi vseh vzrokov, ali glede sestavljenega mikrovaskularnega izida.
Unopened vials, unopened cartridges, not in-use SoloStar pens Store in a refrigerator (2°C-8°C). 
Neodprte viale, neodprti vložki, neuporabljeni SoloStar injekcijski peresniki Shranjujte v hladilniku (2°C - 8°C).
Medication errors have been reported in which other insulins, particularly short-acting insulins, have been accidentally administered instead of insulin glargine. 
O napakah zdravljenja so poročali, ko so bili drugi insulini, posebno kratko delujoči insulini, pomotoma aplicirani namesto insulina glargin.
In a randomised, controlled clinical study, paediatric patients (age range 6 to 15 years) with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus insulin regimen where regular human insulin was used before each meal. 
V randomizirani, kontrolirani klinični študiji so pediatrične bolnike (stare od 6 do 15 let) s sladkorno boleznijo tipa 1 (n=349) 28 tednov zdravili z bazalno-bolusnim insulinskim režimom, pri katerem je bil pred vsakim obrokom uporabljen navadni humani insulin.
If you inject your insulin too often at the same skin site, fatty tissue under the skin at this site may either shrink (lipoatrophy, may affect up to 1 in 100 people) or thicken (lipohypertrophy). 
Če si insulin prepogosto injicirate na istem mestu kože, se lahko podkožno maščevje na tem mestu bodisi skrči (lipoatrofija, pojavi se lahko pri največ 1 od 100 bolnikov) ali zadebeli (lipohipertrofija).
Insulin glargine did not alter the relative risk for CV disease and CV mortality when compared to standard of care. 
Insulin glargin v primerjavi s standardno oskrbo ni spremenil relativega tveganja za KV bolezen ali KV umrljivost.
Important information about some of the ingredients of Lantus 
Pomembne informacije o nekaterih sestavinah zdravila Lantus
At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up. 
Izhodiščno so imeli preiskovanci mediano vrednost HbA1c 6,4 %; mediana vrednost HbA1c med zdravljenjem je segala od 5,9 do 6,4 % v skupini z insulinom glarginom in od 6,2 % do 6,6 % v skupini s standardno oskrbo med celotnim trajanjem spremljanja.
• Skin changes at the injection site 
Spremembe kože na mestu injiciranja
After subcutaneous injection of Lantus in diabetic patients, insulin glargine is rapidly metabolized at the carboxyl terminus of the Beta chain with formation of two active metabolites M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin). 
Po subkutanem injiciranju zdravila Lantus bolnikom s sladkorno boleznijo, se insulin glargin hitro presnovi na karboksilnem koncu verige beta; nastaneta aktivna presnovka M1 (21A-Gly-insulin) in M2 (21A-Gly-des-30B-Thr-insulin).
*Insulin glargine is produced by recombinant DNA technology in Escherichia coli. 
*Insulin glargin je pridobljen s tehnologijo rekombinantne DNA iz bakterij Escherichia coli.
In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests): - If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia). 
V sledečih okoliščinah lahko vodenje vaše sladkorne bolezni zahteva posebno skrb (npr. prilagoditev odmerka insulina, preiskave krvi in urina): Če ste bolni ali se huje poškodujete, se lahko koncentracija krvnega sladkorja zviša (hiperglikemija).
Do not mix Lantus with any other insulins or medicines. 
Ne mešajte zdravila Lantus z nobenim drugim insulinom ali zdravili.
Each pen contains multiple doses. 
Vsak injekcijski peresnik vsebuje več odmerkov.
Generally, the greater and more rapid the decline in blood glucose, the more marked is the phenomenon of counter-regulation and its symptoms (see section 4.4). 
Praviloma so pojav protiregulacije in njegovi simptomi toliko izrazitejši, kolikor večje in hitrejše je zmanjšanje koncentracije glukoze v krvi (glejte poglavje 4.4).
Mean dose of insulin glargine by study end was 0.42 U/kg. 
Povprečni odmerek insulina glargina je bil do konca študije 0,42 enot/kg.
What Lantus is and what it is used for What you need to know before you use Lantus How to use Lantus 
Kaj je zdravilo Lantus in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Lantus Kako uporabljati zdravilo Lantus Možni neželeni učinki
Combination of Lantus with pioglitazone 
Kombinacija zdravila Lantus s pioglitazonom
To prevent the possible transmission of disease, never share your pen with anyone else. 
Da bi preprečili možen prenos bolezni peresnika ne smete z nikomer deliti.
Due to more sustained basal insulin supply with Lantus, less nocturnal but more early morning hypoglycaemia can be expected. 
Zaradi enakomernejšega sproščanja bazalnega insulina je pri zdravilu Lantus mogoče pričakovati manj nočnih, a več zgodnjih jutranjih hipoglikemij.
Pack sizes of 1, 2, 5 and 10 vials of 5 ml or 1 vial of 10 ml. 
Pakiranja po 1, 2, 5 in 10 vial s 5 ml ali po 1 vialo z 10 ml.
The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomised, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus treated with ≤1 antidiabetic oral agent (88% of participants). 
Študija ORIGIN (Outcome Reduction with Initial Glargine INtervention) je bila multicentrična, randomizirana študija s faktorskim načrtom 2 x 2, v katero je bilo vključenih 12.537 sodelujočih z velikim kardiovaskularnim (KV) tveganjem in okvarjeno glukozo na tešče (OGT) ali okvarjeno toleranco za glukozo (OTG) (12 % sodelujočih), ali s sladkorno boleznijo tipa 2, zdravljeno z ≤ 1 peroralnim antidiabetikom (88 % sodelujočih).
A large amount of data on pregnant women (more than 1000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. 
Velika količina podatkov o nosečnicah (več kot 1000 izidov nosečnosti) ne kaže specifičnih neželenih učinkov insulina glargin na nosečnost; prav tako ne kaže, da bi insulin glargin povzročal specifične malformacije, fetotoksične učinke ali toksične učinke na novorojenčka.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard care group. 
Deleža hudih hipoglikemij (prizadeti sodelujoči na 100 sodelujoči-let izpostavljenosti) sta bila 1,05 za insulin glargin in 0,30 za skupino s standardno oskrbo, deleža potrjenih ne-hudih hipoglikemij pa sta bila 7,17 za insulin glargin in 2,44 za skupino s standardno oskrbo.
IGF-1 receptor binding: The affinity of insulin glargine for the human IGF-1 receptor is approximately 5 to 8-fold greater than that of human insulin (but approximately 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1 receptor with slightly lower affinity compared to human insulin. 
Vezava na receptorje za IGF-1: Afiniteta insulina glargina za človeški receptor IGF-1 je približno 5do 8-krat večja kot afiniteta humanega insulina (vendar približno 70- do 80-krat manjša kot afiniteta IGF-1), presnovka M1 in M2 pa se na receptor za IGF-1 vežeta z nekoliko manjšo afiniteto kot humani insulin.
Insulin treatment can cause the body to produce antibodies to insulin (substances that act against insulin). 
Uporaba insulina lahko povzroči nastanek protiteles proti insulinu (snovi, ki delujejo proti insulinu).
• If still no insulin comes out, the needle may be blocked. 
• Če insulin še vedno ne pokaže, je igla morda zamašena.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered. 
V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper- ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustrezno tehniko injiciranja in vse druge pomembne dejavnike.
Such reactions to insulin (including insulin glargine) or the excipients may, for example, be associated with generalised skin reactions, angio-oedema, bronchospasm, hypotension and shock, and may be life-threatening. 
Takšne reakcije na insulin (tudi na insulin glargin) ali pomožne snovi so lahko povezane tudi npr. z generaliziranimi kožnimi reakcijami, angioedemom, bronhospazmom, hipotenzijo in šokom ter so lahko smrtno nevarne.
The primary aim of demonstrating non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and there was a trend to an increase of hypoglycemic events with insulin glargine [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. 
Primarni cilj, dokazati neinferiornost insulina glargin v primerjavi z insulinom NPH v zvezi z hipoglikemijami, ni bil dokazan - opazen je bil trend povečanja hipoglikemičnih dogodkov z insulinom glargin [razmerje insulin glargin : NPH (95 % IZ) = 1,18 (0,97-1,44)].
Manufacturers 
Izdelovalca
Do not use SoloStar if it is damaged or not working properly, it has to be discarded and a new SoloStar has to be used. 
Ne uporabljajte SoloStarja, če je poškodovan ali ne deluje pravilno; v takšnem primeru ga zavrzite in uporabite nov SoloStar.
Lantus should not be administered intravenously. 
Zdravila Lantus se ne sme dajati intravensko.
The prolonged duration of action of Lantus is dependent on its injection into subcutaneous tissue. 
Podaljšano delovanje zdravila Lantus je povezano s tem, da je injiciran v podkožno tkivo.
Only use needles that are compatible for use with SoloStar (see “SoloStar Instructions for Use”). 
Uporabljajte le igle, primerne za uporabo s SoloStarjem (glejte Navodila za uporabo SoloStarja).
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder. 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom
Beta-blockers like other sympatholytic medicines (such as clonidine, guanethidine, and reserpine) may weaken or suppress entirely the first warning symptoms which help you to recognise a hypoglycaemia. 
Antagonisti adrenergičnih receptorjev beta lahko, tako kot druga simpatikolitična zdravila (kot so klonidin, gvanetidin in reserpin), oslabijo ali popolnoma preprečijo prve opozorilne simptome, ki vam pomagajo prepoznati hipoglikemijo.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with Lantus is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of Lantus. 
Farmakokinetični in farmakodinamski izsledki kažejo, da učinek subkutano injiciranega zdravila Lantus temelji predvsem na izpostavljenosti presnovku M1. Insulin glargin in presnovek M2 pri veliki večini preiskovancev nista bila zaznavna; če sta bila zaznavna, pa njuna koncentracija ni bila odvisna od uporabljenega odmerka zdravila Lantus.
Lantus is injected under the skin. 
Zdravilo Lantus se injicira pod kožo.
• Adolescents and children aged 2 years and older patients Safety and efficacy of Lantus have been established in adolescents and children aged 2 years and older (see section 5.1). 
Varnost in učinkovitost zdravila Lantus sta ugotovljeni pri mladostnikih in otrocih, starih 2 leti in več (glejte poglavje 5.1).
Participants were randomised (1:1) to receive insulin glargine (n=6264), titrated to reach FPG ≤95 mg/dl (5.3 mM), or standard care (n=6273). 
Preiskovanci so bili v razmerju 1:1 randomizirani na prejemanje insulina glargina (n = 6264), titriranega tako, da je bila dosežena glukoza v plazmi na tešče ≤ 95 mg/dL (5,3 mM), ali na standardno oskrbo (n = 6273).
Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will: - determine how much Lantus per day you will need and at what time, - tell you when to check your blood sugar level, and whether you need to carry out urine tests, - tell you when you may need to inject a higher or lower dose of Lantus. 
Vaš zdravnik bo, glede na vaš način življenja, izvide meritev vašega krvnega sladkorja (glukoze) in prejšnjo uporabo insulina: - določil, koliko zdravila Lantus na dan potrebujete in ob katerem času, - povedal, kdaj merite krvni sladkor in ali morate opravljati teste urina, - povedal, kdaj boste morda morali povečati ali zmanjšati odmerek zdravila Lantus.
One hundred forty three of the patients treated with insulin glargine in this study continued treatment with insulin glargine in an uncontrolled extension study with mean duration of follow-up of 2 years. 
Stotriinštirideset (143) bolnikov, ki so v tej študiji uporabljali insulin glargin, je zdravljenje z njim nadaljevalo v nekontrolirani podaljšani študiji, v kateri je povprečno spremljanje trajalo 2 leti.
Sanofi S.p.A., Via Valcanello, 4 03012 Anagni (FR), Italy. 
Sanofi S.p.A., Via Valcanello 4 03012 Anagni (FR) Italija
At the last on-treatment visit, there was a mean increase in body weight from baseline of 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the standard care group. 
Na zadnjem obisku med zdravljenjem je bilo povprečno povečanje telesne mase od izhodišča v skupini z insulinom glarginom 1,4 kg in povprečno zmanjšanje v skupini s standardno oskrbo 0,8 kg.
If you forget to use Lantus 
Če ste pozabili uporabiti zdravilo Lantus
Do not soak, wash or lubricate the pen as this may damage it. 
Injekcijskega peresnika ne smete namakati, umivati ali mazati, ker ga s tem lahko poškodujete.
Switch from other insulins to Lantus 
Prehod z drugih insulinov na zdravilo Lantus
If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain and oedema. 
Pri uporabi omenjene kombinacije, je pri bolnikih potrebno nadzorovati znake in simptome srčnega popuščanja, povečanja telesne mase in pojava edemov.
Read all of this leaflet carefully including the Instructions for Use of Lantus SoloStar, pre-filled pen, before you start using this medicine because it contains important information for you. 
Pred začetkom uporabe zdravila natančno preberite navodilo, vključno z navodilom za uporabo zdravila Lantus SoloStar, napolnjen injekcijski peresnik, ker vsebuje za vas pomembne podatke!
Dose adjustment may also be required, for example, if the patient's weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypo- or hyperglycaemia (see section 4.4). 
Prilagoditev odmerka je lahko potrebna tudi, če se npr. spremeni bolnikova telesna masa, način življenja ali čas apliciranja insulina, ali se pojavijo kakšne druge okoliščine, ki povečajo nagnjenost k hipo- ali hiperglikemiji (glejte poglavje 4.4).
Always use a new pen if you notice that your blood sugar control is unexpectedly getting worse. 
Vedno uporabite nov injekcijski peresnik, če opazite, da se urejenost vašega krvnega sladkorja nepričakovano poslabša.
The pen plunger moves with each dose. 
Bat se premakne ob vsakem odmerku.
A new needle must be attached before each use. 
Pred vsako uporabo morate namestiti novo iglo.
Lantus 100 units/ml solution for injection in a vial For further details on handling, see section 6.6. 
Lantus 100 enot/ml raztopina za injiciranje v viali Za dodatne podrobnosti o ravnanju glejte poglavje 6.6.
Although Lantus contains the same active substance as Toujeo (insulin glargine 300 units/ml), these medicines are not interchangeable. 
Zdravilo Lantus sicer vsebuje isto zdravilno učinkovino kot zdravilo Toujeo (insulin glargin 300 enot/ml), vendar ti zdravili nista medsebojno zamenljivi.
The recovery of hypoglycaemia may be delayed because Lantus has a long action. 
Okrevanje po hipoglikemiji je zaradi dolgega delovanja zdravila Lantus lahko upočasnjeno.
Not all of these pens may be marketed in your country (see section 4.2 and 6.6) 
Na trgu ni nujno vseh navedenih injekcijskih peresnikov (glejte poglavji 4.2 in 6.6).
The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type 1 diabetic patients was markedly lower than what would be required for a halfmaximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor. 
Celotna terapevtska koncentracija insulina (insulina glargina in njegovih presnovkov) je bila pri bolnikih s sladkorno boleznijo tipa 1 bistveno manjša od koncentracije, potrebne za polovično največjo zasedenost receptorjev za IGF-1 in posledično aktivacijo mitogeno-proliferacijske poti, ki jo sproža receptor za IGF-1.
If you use more Lantus than you should 
Če ste uporabili večji odmerek zdravila Lantus, kot bi smeli
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone (oral anti-diabetic medicine used to treat type 2 diabetes mellitus) and insulin experienced the development of heart failure. 
Nekateri bolniki, ki imajo dolgotrajno sladkorno bolezen tipa 2 in srčno obolenje ali so doživeli srčno kap ter so bili sočasno zdravljeni s pioglitazonom (peroralni antidiabetik namenjen zdravljenju sladkorne bolezni tipa 2) in insulinom, so doživeli razvoj srčnega popuščanja.
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure. 
Ob uporabi pioglitazona v kombinaciji z insulinom, so poročali o primerih srčnega popuščanja, predvsem pri bolnikih z dejavniki tveganja za razvoj srčnega popuščanja.
What Lantus looks like and contents of the pack 
Izgled zdravila Lantus in vsebina pakiranja
In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin requirements. 
Pri starejših bolnikih lahko napredujoče slabšanje delovanja ledvic povzroči stalno zmanjševanje potrebe po insulinu.
B. Dispose of the needle safely, as instructed by your doctor, pharmacist or nurse. 
B. Iglo varno zavrzite, kot vam je naročil vaš zdravnik, farmacevt ali medicinska sestra.
In general, the side effects in children and adolescents of 18 years of age or less are similar to those seen in adults. 
Navadno so neželeni učinki pri otrocih in mladostnikih starih  18 let podobni neželenim učinkom pri odraslih.
C. Check the appearance of your insulin. 
C. Preverite videz insulina.
Unopened: 
Neodprt:
Severe allergic reactions to insulins may become life-threatening. 
Huda alergijska reakcije na insuline lahko postane smrtno nevarna.
Insulin receptor binding: In vitro studies indicate that the affinity of insulin glargine and its metabolites M1 and M2 for the human insulin receptor is similar to the one of human insulin. 
Vezava na insulinske receptorje: Študije in vitro kažejo, da je afiniteta insulina glargina in njegovih presnovkov M1 in M2 za človeške insulinske receptorje podobna afiniteti humanega insulina.
Do not use this SoloStar if the insulin is cloudy, coloured or has particles. 
SoloStarja ne uporabite, če je insulin moten, obarvan ali so v njem delci.
To reduce the risk of hypoglycemia, patients who are changing their basal insulin regimen from an insulin regimen with once daily insulin glargine 300 units/ml to a once daily regimen with Lantus should reduce their dose by approximately 20%. 
Da bi zmanjšali tveganje za hipoglikemijo, je treba bolnikom, ki spreminjajo odmerjanje bazalnega insulina z insulina glargina 300 enot/ml enkrat na dan na zdravilo Lantus enkrat na dan, odmerek zmanjšati za približno 20 %.
It is recommended that the date of the first use from the vial be noted on the label. 
Priporočljivo je na nalepko vpisati datum prve uporabe viale.
If you stop using Lantus 
Če ste prenehali uporabljati zdravilo Lantus
Switch from twice daily NPH insulin to Lantus 
Prehod z insulina NPH dvakrat na dan na zdravilo Lantus
You should contact your doctor for advice on driving if: - you have frequent episodes of hypoglycaemia, - the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent. 
Z zdravnikom se pogovorite, ali je priporočljivo, da vozite, če: - imate pogoste hipoglikemije, - so prvi opozorilni znaki hipoglikemije šibki ali jih sploh nimate.
Do not stop Lantus without speaking to a doctor, who will tell you what needs to be done. 
Ne prenehajte zdravljenja z zdravilom Lantus, ne da bi se pogovorili z zdravnikom.
Read carefully the "SoloStar Instructions for Use" included in this package leaflet. 
Natančno preberite "Navodila za uporabo SoloStarja", ki jih vključuje to navodilo.
Only use needles that are compatible for use with SoloStar. 
Uporabljajte le igle, primerne za uporabo s SoloStarjem.
The Lantus Solostar is grey with a purple injection button. 
Lantus SoloStar je siv in ima škrlaten gumb za injiciranje.
The graph above shows the activity profiles over time of insulin glargine and NPH insulin. 
Zgornji graf prikazuje časovni potek delovanja insulina glargin in insulina NPH.
Only use needles that are compatible for use with 
Uporabljajte le igle, primerne za uporabo s